FDA Offers Guidance on Submitting NGS Data in Support of Antiviral Drugs

FDA Offers Guidance on Submitting NGS Data in Support of Antiviral Drugs

Publication date: Jul 19, 2019

The US Food and Drug Administration this week issued final guidance concerning the submission of next-generation sequencing data from resistance assessments performed in the development of antiviral drugs.

Concepts Keywords
Antiviral Drugs Antiviral drug
FDA Health
Sequencing Government agencies
Articles
Biocides

Semantics

Type Source Name
disease MESH development

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *